{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:51:10Z","timestamp":1779249070982,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Foundation of the State of Sao Paulo - FAPESP","award":["FAPESP 2012\/51692-7"],"award-info":[{"award-number":["FAPESP 2012\/51692-7"]}]},{"name":"Research Foundation of the State of Sao Paulo","award":["Fapesp 2014\/50983-3"],"award-info":[{"award-number":["Fapesp 2014\/50983-3"]}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["CNPq  428793\/2016-9"],"award-info":[{"award-number":["CNPq  428793\/2016-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca, Brazil","award":["ESR 14-10726"],"award-info":[{"award-number":["ESR 14-10726"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low-density lipoprotein cholesterol targets, but their effects on other lipids are less reported. This study was designed to examine lipid changes in subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies. Twenty patients with STEMI were randomized to be treated with rosuvastatin 20\u00a0mg QD or simvastatin 40\u00a0mg combined with ezetimibe 10\u00a0mg QD for 30\u00a0days. Fasting blood samples were collected on the first day (D1) and after 30\u00a0days (D30). Lipidomic analysis was performed using the Lipidyzer platform. Similar classic lipid profile was obtained in both groups of lipid-lowering therapies. However, differences with the lipidomic analysis were observed between D30 and D1 for most of the analyzed classes. Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin. Correlation studies between classic lipid profiles and lipidomic results showed different information. These findings seem relevant, due to the involvement of these lipid classes in crucial mechanisms of atherosclerosis, and may account for residual cardiovascular risk.<\/jats:p>\n                  <jats:p>Randomized clinical trial: ClinicalTrials.gov, NCT02428374, registered on 28\/09\/2014.<\/jats:p>","DOI":"10.1038\/s41598-021-95455-z","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:37:25Z","timestamp":1628602645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction"],"prefix":"10.1038","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02428374","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Aline","family":"Klassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Tedesco","family":"Faccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Raissa Costa","family":"Picossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla Bento Matos Cruz","family":"Derogis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"dos Santos Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Soriano","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sussulini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa Casta\u00f1eda Santa","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela Tudela","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie Caroline","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Martins Figueiredo","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Franco Maggi","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Izar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Antonio Helfenstein","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"95455_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5","author":"C Baigent","year":"2010","unstructured":"Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5 (2010).","journal-title":"Lancet"},{"key":"95455_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1801174 (2018).","journal-title":"N. Engl. J. Med."},{"key":"95455_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1711","author":"GG Schwartz","year":"2001","unstructured":"Schwartz, G. G. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA https:\/\/doi.org\/10.1001\/jama.285.13.1711 (2001).","journal-title":"JAMA"},{"key":"95455_CR4","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387\u20132397 (2015).","journal-title":"N. Engl. J. Med."},{"key":"95455_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.01.003","author":"I Sutter","year":"2016","unstructured":"Sutter, I. et al. Decreased phosphatidylcholine plasmalogens\u2014A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. Atherosclerosis https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.003 (2016).","journal-title":"Atherosclerosis"},{"key":"95455_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.12754","author":"A Koivuniemi","year":"2017","unstructured":"Koivuniemi, A. The biophysical properties of plasmalogens originating from their unique molecular architecture. FEBS Lett. https:\/\/doi.org\/10.1002\/1873-3468.12754 (2017).","journal-title":"FEBS Lett."},{"key":"95455_CR7","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1080\/21691401.2019.1665058","volume":"47","author":"X Wang","year":"2019","unstructured":"Wang, X., Huang, H., Su, C., Zhong, Q. & Wu, G. Cilostazol ameliorates high free fatty acid (FFA)-induced activation of NLRP3 inflammasome in human vascular endothelial cells. Artif. Cells Nanomed. Biotechnol. 47, 3704\u20133710 (2019).","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"95455_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nature08938","author":"P Duewell","year":"2010","unstructured":"Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature https:\/\/doi.org\/10.1038\/nature08938 (2010).","journal-title":"Nature"},{"key":"95455_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.06.010","author":"H Ghanim","year":"2017","unstructured":"Ghanim, H. et al. Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.06.010 (2017).","journal-title":"Atherosclerosis"},{"key":"95455_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.10.029","author":"JM Choi","year":"2014","unstructured":"Choi, J. M., Kim, T. E., Cho, J. Y., Lee, H. J. & Jung, B. H. Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. https:\/\/doi.org\/10.1016\/j.jchromb.2013.10.029 (2014).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"95455_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1039\/C4MB00414K","volume":"11","author":"MN Triba","year":"2015","unstructured":"Triba, M. N. et al. PLS\/OPLS models in metabolomics: The impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Mol. Biosyst. 11, 13\u201319 (2015).","journal-title":"Mol. Biosyst."},{"key":"95455_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2337\/diab.30.2.S60","volume":"30","author":"RW Mahley","year":"1981","unstructured":"Mahley, R. W. Cellular and molecular biology of lipoprotein metabolism in atherosclerosis. Diabetes 30, 60\u201365 (1981).","journal-title":"Diabetes"},{"key":"95455_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.200","author":"P Jiao","year":"2011","unstructured":"Jiao, P. et al. FFA-induced adipocyte inflammation and insulin resistance: Involvement of ER stress and IKK\u03b2 pathways. Obesity https:\/\/doi.org\/10.1038\/oby.2010.200 (2011).","journal-title":"Obesity"},{"key":"95455_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1039\/b700706j","volume":"3","author":"DA Blasiole","year":"2007","unstructured":"Blasiole, D. A., Davis, R. A. & Attie, A. D. The physiological and molecular regulation of lipoprotein assembly and secretion. Mol. Biosyst. 3, 608\u2013619 (2007).","journal-title":"Mol. Biosyst."},{"key":"95455_CR15","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","volume":"1859","author":"JN van der Veen","year":"2017","unstructured":"van der Veen, J. N. et al. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys. Acta - Biomembr. 1859, 1558\u20131572 (2017).","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"95455_CR16","doi-asserted-by":"publisher","first-page":"4829180","DOI":"10.1155\/2017\/4829180","volume":"2017","author":"D Patel","year":"2017","unstructured":"Patel, D. & Witt, S. N. Ethanolamine and phosphatidylethanolamine: Partners in health and disease. Oxid. Med. Cell. Longev. 2017, 4829180 (2017).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"95455_CR17","doi-asserted-by":"publisher","first-page":"105444","DOI":"10.1016\/j.envint.2019.105444","volume":"136","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. PM2.5-induced inflammation and lipidome alteration associated with the development of atherosclerosis based on a targeted lipidomic analysis. Environ. Int. 136, 105444 (2020).","journal-title":"Environ. Int."},{"key":"95455_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315530","author":"VC Vasile","year":"2021","unstructured":"Vasile, V. C. et al. Ceramide scores predict cardiovascular risk in the community. Arterioscler. Thromb. Vasc. Biol. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315530 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"95455_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.09.004","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Associations between plasma ceramides and mortality in patients with coronary artery disease. Atherosclerosis https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.09.004 (2020).","journal-title":"Atherosclerosis"},{"key":"95455_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/metabo10040163","author":"M Ding","year":"2020","unstructured":"Ding, M. & Rexrode, K. M. A review of lipidomics of cardiovascular disease highlights the importance of isolating lipoproteins. Metabolites https:\/\/doi.org\/10.3390\/metabo10040163 (2020).","journal-title":"Metabolites"},{"key":"95455_CR21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1216063","author":"P Libby","year":"2013","unstructured":"Libby, P. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMra1216063 (2013).","journal-title":"N. Engl. J. Med."},{"key":"95455_CR22","first-page":"227","volume":"1730","author":"D Erasmus","year":"2016","unstructured":"Erasmus, D. Chapter 15. New Testam. Scholarsh. 1730, 227\u2013236 (2016).","journal-title":"New Testam. Scholarsh."},{"key":"95455_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy310","author":"PM Ridker","year":"2018","unstructured":"Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehy310 (2018).","journal-title":"Eur. Heart J."},{"key":"95455_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/nu11092022","volume":"11","author":"AIS Sobczak","year":"2019","unstructured":"Sobczak, A. I. S., Blindauer, C. A. & Stewart, A. J. Changes in plasma free fatty acids associated with type-2 diabetes. Nutrients 11, 2 (2019).","journal-title":"Nutrients"},{"key":"95455_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu10040432","volume":"10","author":"MM Rogero","year":"2018","unstructured":"Rogero, M. M. & Calder, P. C. Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients 10, 1\u201319 (2018).","journal-title":"Nutrients"},{"key":"95455_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0357-5","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A., Gao, L., Thakur, A., Siu, P. M. & Lai, C. W. K. Role of free fatty acids in endothelial dysfunction. J. Biomed. Sci. https:\/\/doi.org\/10.1186\/s12929-017-0357-5 (2017).","journal-title":"J. Biomed. Sci."},{"key":"95455_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.029","author":"AC Carpentier","year":"2018","unstructured":"Carpentier, A. C. Abnormal myocardial dietary fatty acid metabolism and diabetic cardiomyopathy. Can. J. Cardiol. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.029 (2018).","journal-title":"Can. J. Cardiol."},{"key":"95455_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/bcp.12854","volume":"81","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar, A. et al. Statin therapy and plasma free fatty acids: A systematic review and meta-analysis of controlled clinical trials. Br. J. Clin. Pharmacol. 81, 807\u2013818 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"95455_CR29","doi-asserted-by":"publisher","DOI":"10.2174\/092986707782793899","author":"T Matsumoto","year":"2007","unstructured":"Matsumoto, T., Kobayashi, T. & Kamata, K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem. https:\/\/doi.org\/10.2174\/092986707782793899 (2007).","journal-title":"Curr. Med. Chem."},{"key":"95455_CR30","doi-asserted-by":"publisher","DOI":"10.1159\/000473879","author":"H Tanaka","year":"2017","unstructured":"Tanaka, H. et al. Lysophosphatidylcholine acyltransferase-3 expression is associated with atherosclerosis progression. J. Vasc. Res. https:\/\/doi.org\/10.1159\/000473879 (2017).","journal-title":"J. Vasc. Res."},{"key":"95455_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20051149","volume":"20","author":"SH Law","year":"2019","unstructured":"Law, S. H. et al. An updated review of lysophosphatidylcholine metabolism in human diseases. Int. J. Mol. Sci. 20, 1\u201324 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"95455_CR32","first-page":"2","volume":"8","author":"C Fernandez","year":"2013","unstructured":"Fernandez, C. et al. Plasma lipid composition and risk of developing cardiovascular disease. PLoS ONE 8, 2 (2013).","journal-title":"PLoS ONE"},{"key":"95455_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121326","author":"PA Mundra","year":"2018","unstructured":"Mundra, P. A. et al. Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention. JCI insight https:\/\/doi.org\/10.1172\/jci.insight.121326 (2018).","journal-title":"JCI insight"},{"issue":"7","key":"95455_CR34","doi-asserted-by":"publisher","first-page":"e1001255","DOI":"10.1371\/journal.pmed.1001255","volume":"9","author":"K Khaw","year":"2012","unstructured":"Khaw, K., Friesen, M. D., Riboli, E., Luben, R. & Wareham, N. Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: The EPIC-Norfolk prospective study. PLoS Med. 9(7), e1001255 (2012).","journal-title":"PLoS Med."},{"key":"95455_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310789","author":"CK Ward-caviness","year":"2017","unstructured":"Ward-caviness, C. K. et al. Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers. Heart https:\/\/doi.org\/10.1136\/heartjnl-2016-310789 (2017).","journal-title":"Heart"},{"key":"95455_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.199281","author":"J Yeboah","year":"2010","unstructured":"Yeboah, J. et al. Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-ethnic study of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. https:\/\/doi.org\/10.1161\/ATVBAHA.109.199281 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"95455_CR37","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802321709","author":"SC Bergheanu","year":"2008","unstructured":"Bergheanu, S. C. et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: Investigating differential effects among statins. Curr. Med. Res. Opin. https:\/\/doi.org\/10.1185\/03007990802321709 (2008).","journal-title":"Curr. Med. Res. Opin."},{"key":"95455_CR38","volume-title":"Regulation of Endogenic Metabolites by Rosuvastatin in Hyperlipidemia Patients: An Integration of Metabolomics and Lipidomics. Chemistry and Physics of Lipids","author":"H Lee","year":"2018","unstructured":"Lee, H. et al. Regulation of Endogenic Metabolites by Rosuvastatin in Hyperlipidemia Patients: An Integration of Metabolomics and Lipidomics. Chemistry and Physics of Lipids Vol. 214 (Elsevier Ireland Ltd, 2018)."},{"key":"95455_CR39","doi-asserted-by":"publisher","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","volume":"99","author":"TWK Ng","year":"2014","unstructured":"Ng, T. W. K. et al. Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J. Clin. Endocrinol. Metab. 99, E2335\u2013E2340 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"95455_CR40","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1161\/CIRCULATIONAHA.113.002500","volume":"129","author":"C Stegemann","year":"2014","unstructured":"Stegemann, C. et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based bruneck study. Circulation 129, 1821\u20131831 (2014).","journal-title":"Circulation"},{"key":"95455_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085724","author":"A Sigruener","year":"2014","unstructured":"Sigruener, A. et al. Glycerophospholipid and sphingolipid species and mortality: The Ludwigshafen risk and cardiovascular health (LURIC) study. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0085724 (2014).","journal-title":"PLoS ONE"},{"key":"95455_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023233","author":"ZH Alshehry","year":"2016","unstructured":"Alshehry, Z. H. et al. Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023233 (2016).","journal-title":"Circulation"},{"key":"95455_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.10.022","author":"JM Cheng","year":"2015","unstructured":"Cheng, J. M. et al. Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.10.022 (2015).","journal-title":"Atherosclerosis"},{"key":"95455_CR44","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P081281","author":"S Anroedh","year":"2018","unstructured":"Anroedh, S. et al. Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. J. Lipid Res. https:\/\/doi.org\/10.1194\/jlr.P081281 (2018).","journal-title":"J. Lipid Res."},{"key":"95455_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw148","author":"R Laaksonen","year":"2016","unstructured":"Laaksonen, R. et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehw148 (2016).","journal-title":"Eur. Heart J."},{"key":"95455_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jjcc.2012.07.008","volume":"60","author":"KH Yun","year":"2012","unstructured":"Yun, K. H., Shin, S., Ko, J. S. & Rhee, S. J. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. J. Cardiol. 60, 383\u2013388 (2012).","journal-title":"J. Cardiol."},{"key":"95455_CR47","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1185\/030079906X132721","volume":"22","author":"AL Catapano","year":"2006","unstructured":"Catapano, A. L. et al. Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22, 2041\u20132053 (2006).","journal-title":"Curr. Med. Res. Opin."},{"key":"95455_CR48","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.clinthera.2004.12.015","volume":"26","author":"JK Malone","year":"2004","unstructured":"Malone, J. K., Kerr, L. F., Campaigne, B. N., Sachson, R. A. & Holcombe, J. H. Combined therapy with insulin lispro mix 75\/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin. Ther. 26, 2034\u20132044 (2004).","journal-title":"Clin. Ther."},{"key":"95455_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jchromb.2013.10.029","volume":"944","author":"JM Choi","year":"2014","unstructured":"Choi, J. M., Kim, T. E., Cho, J. Y., Lee, H. J. & Jung, B. H. Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 944, 157\u2013165 (2014).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"95455_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.11.075","author":"B Pitt","year":"2008","unstructured":"Pitt, B., Loscalzo, J., Y\u010das, J. & Raichlen, J. S. Lipid levels after acute coronary syndromes. J. Am. Coll. Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2007.11.075 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"95455_CR51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1089\/omi.2016.0178","volume":"21","author":"S Rai","year":"2017","unstructured":"Rai, S. & Bhatnagar, S. Novel lipidomic biomarkers in hyperlipidemia and cardiovascular diseases: An integrative biology analysis. Omi. A J. Integr. Biol. 21, 132\u2013142 (2017).","journal-title":"Omi. A J. Integr. Biol."},{"key":"95455_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13063-017-2361-1","volume":"18","author":"FAH Fonseca","year":"2017","unstructured":"Fonseca, F. A. H. et al. Effects of four antiplatelet\/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T types of lymphocytes evaluation in acute my. Trials 18, 2 (2017).","journal-title":"Trials"},{"key":"95455_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom11020326","volume":"11","author":"P Pik\u00f3","year":"2021","unstructured":"Pik\u00f3, P. et al. Obesity-related changes in human plasma lipidome determined by the lipidyzer platform. Biomolecules 11, 1\u201320 (2021).","journal-title":"Biomolecules"},{"issue":"9","key":"95455_CR54","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3390\/nu10091314","volume":"10","author":"Franko","year":"2018","unstructured":"Franko, et al. Dissociation of fatty liver and insulin resistance in I148M PNPLA3 carriers: Differences in diacylglycerol (DAG) FA18:1 lipid species as a possible explanation. Nutrients 10(9), 1314. https:\/\/doi.org\/10.3390\/nu10091314 (2018).","journal-title":"Nutrients"},{"key":"95455_CR55","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1021\/acs.jproteome.9b00289","volume":"19","author":"Z Cao","year":"2020","unstructured":"Cao, Z. et al. Evaluation of the performance of lipidyzer platform and its application in the lipidomics analysis in mouse heart and liver. J. Proteome Res. 19, 2742\u20132749 (2020).","journal-title":"J. Proteome Res."},{"key":"95455_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35807-4","author":"K Contrepois","year":"2018","unstructured":"Contrepois, K. et al. Cross-platform comparison of untargeted and targeted lipidomics approaches on aging mouse plasma. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-018-35807-4 (2018).","journal-title":"Sci. Rep."},{"key":"95455_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/metabo9060109","volume":"9","author":"JD Quell","year":"2019","unstructured":"Quell, J. D. et al. Characterization of bulk phosphatidylcholine compositions in human plasma using side-chain resolving lipidomics. Metabolites 9, 2 (2019).","journal-title":"Metabolites"},{"key":"95455_CR58","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s00216-020-02460-8","volume":"412","author":"JC Alarcon-Barrera","year":"2020","unstructured":"Alarcon-Barrera, J. C. et al. Lipid metabolism of leukocytes in the unstimulated and activated states. Anal. Bioanal. Chem. 412, 2353\u20132363 (2020).","journal-title":"Anal. Bioanal. Chem."},{"key":"95455_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-1-4939-7592-1_15","volume":"1730","author":"BK Ubhi","year":"2018","unstructured":"Ubhi, B. K. Direct infusion-tandem mass spectrometry (DI-MS\/MS) analysis of complex lipids in human plasma and serum using the LipidyzerTM platform. Clin. Metabolomics 1730, 227\u2013236 (2018).","journal-title":"Clin. Metabolomics"},{"key":"95455_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.05.048","author":"HG Gika","year":"2008","unstructured":"Gika, H. G., Macpherson, E., Theodoridis, G. A. & Wilson, I. D. Evaluation of the repeatability of ultra-performance liquid chromatography-TOF-MS for global metabolic profiling of human urine samples. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. https:\/\/doi.org\/10.1016\/j.jchromb.2008.05.048 (2008).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"95455_CR61","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. FDA (2001)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95455-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95455-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95455-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:07:24Z","timestamp":1670051244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95455-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95455"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95455-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-154365\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"24 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15973"}}